Om Megashree Pharmaceuticals Limited is concluding the offering of 14,76,000 units of IPO shares, each with a nominal value of Rs 100, starting today, the 3rd Chaitra, 2081. The sale opened to the public on the 27th Falgun, 2081.
The company boasts an issued capital of Rs. 60 Crores, from which 30%, or 18,00,000 unit shares valued at Rs. 18 Crores, will be available later to the general populace. Of this public offering, 10% of the shares, encompassing 1,80,000 units, have been allocated for Nepali citizens employed abroad. From the total of 18,00,000 units, 90,000 (that is, 5% of 18,00,000) have been earmarked for mutual funds, with 54,000 (or 3% of 18,00,000) units designated for the company’s employees. The remaining 14,76,000 units are set aside for the public, with the offering closing today.
Prabhu Capital Limited has been appointed as the issue manager. Applications can be made for a minimum of 10 units and a maximum of 10,000 units.
As reported by CDSC, 16,18,978 applicants have submitted requests for 1,96,00,430 units valued at Rs. 1.96 Arba. Consequently, the offering has already been oversubscribed by 13.27 times.
CARE Ratings Nepal Limited (CRNL) has reaffirmed the ‘CARE-NP BB- (Is)’ rating for Om Megashree Pharmaceuticals Limited (OMPL), reflecting a moderate likelihood of default in meeting timely financial obligations. Furthermore, CRNL has maintained the ‘CARE-NP BB-’ rating for OMPL’s long-term banking facilities and the ‘CARE-NP A4’ rating for its short-term banking facilities.
Established on June 12, 2016, Om Megashree Pharmaceuticals Limited is a publicly traded company in Nepal, initiated by a consortium of institutional and private investors. The company produces pharmaceutical goods at its plant located in Chitwan and commenced partial operations on February 19, 2024.
